New Brunswick, N.J. (October 28, 2021) – Combining electroencephalogram (EEG) data with clinical observations can help doctors to better determine whether generalized epilepsy patients will respond to ...

Frederic L.W.V.J. Schaper, MD, PhD, director of Epilepsy Network Mapping at the Center for Brain Circuit Therapeutics at Brigham and Women’s Hospital and an instructor of neurology at Harvard Medical ...

People with generalized epilepsy who have seizures arising from both sides of the brain simultaneously, have a higher risk of obstructive sleep apnea (OSA) compared to patients who have focal epilepsy ...

J Child Neurol. 2004;19(8):571-578. Patients with an isolated visually induced seizure in special circumstances, with or without a photoparoxysmal response on the EEG. This group comprises patients ...

Jan. 21, 2004 — Compared with lamotrigine and topiramate, valproate is the most effective treatment for idiopathic generalized epilepsy (IGE), according to the results of a retrospective study ...

MOUNTAIN VIEW, Calif., December 08, 2025--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the ...

NEW ORLEANS -- About half of women with frontal lobe epilepsy experienced more frequent seizures during pregnancy, researchers reported here. "Women with frontal lobe epilepsy have the highest risk ...

Researchers aimed to identify the characteristics, treatment pathways, and outcomes associated with epilepsy with eyelid myoclonia (EEM). Epilepsy with eyelid myoclonia (EEM) is a rare and ...

(HealthDay)—Patients with generalized epilepsy have a higher risk for obstructive sleep apnea (OSA), according to a study published in the October issue of Epilepsy & Behavior. Matthew T. Scharf, M.D.

More than 3.4 million people in the United States have epilepsy, so it is a relatively common diagnosis. In fact, it is the fourth-most common neurologic condition in the world. November is National ...

-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...